» Articles » PMID: 21900254

T Cell Activation by Terminal Complex of Complement and Immune Complexes

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2011 Sep 9
PMID 21900254
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

T cell hyperactivation and complement consumption are prominent features of the immunopathology of systemic lupus erythematosus. Although complement activation is secondary to autoantibodies that form immune complexes (ICs), the trigger for alterations in human peripheral blood T cells is poorly understood. To study the impact (on T cells) of several types of preformed ICs and terminal complement complex, also referred to as C5b-9, we incubated these immune reactants with peripheral blood naive CD4(+) T cells as well as Jurkat cells and analyzed their effects on cellular behavior. We first assembled the C5b-9 in situ on the membrane and observed its assembly primarily on a single site where it promoted aggregation of membrane rafts and recruitment of the CD3 signaling complex. However, C5b-9 alone did not initiate proliferation or commencement of downstream signaling events associated with T cell activation. When T cells were treated with ICs together with nonlytic C5b-9, changes associated with T cell activation by possible antigen engagement then occurred. T cell antigen receptor signaling proteins, including ζ-chain, ZAP-70, Syk, Src, and Lck, were phosphorylated and organized in a synapse-like structure. The cytoskeleton formed F-actin spindles and a distal pole complex, resulting in a bipolar distribution of phosphorylated ezrin-radixin-moesin and F-actin. Furthermore, ICs and nonlytic C5b-9 induced T cell proliferation and IFN-γ production. These results raise the possibility that ICs and the nonlytic C5b-9 modulate T cell-mediated responses in systemic lupus erythematosus and other related chronic inflammatory disorders.

Citing Articles

sFgl2-Treg Positive Feedback Pathway Protects against Atherosclerosis.

An T, Guo M, Fan C, Huang S, Liu H, Liu K Int J Mol Sci. 2023; 24(3).

PMID: 36768661 PMC: 9916961. DOI: 10.3390/ijms24032338.


Cd59 and inflammation regulate Schwann cell development.

Wiltbank A, Steinson E, Criswell S, Piller M, Kucenas S Elife. 2022; 11.

PMID: 35748863 PMC: 9232220. DOI: 10.7554/eLife.76640.


A Dual Role of Complement Activation in the Development of Fulminant Hepatic Failure Induced by Murine-Beta-Coronavirus Infection.

Fang Y, Guo Y, Gao T, Han X, Jiang Y, Li M Front Cell Infect Microbiol. 2022; 12:880915.

PMID: 35573780 PMC: 9099255. DOI: 10.3389/fcimb.2022.880915.


Complement After Trauma: Suturing Innate and Adaptive Immunity.

Chakraborty S, Karasu E, Huber-Lang M Front Immunol. 2018; 9:2050.

PMID: 30319602 PMC: 6165897. DOI: 10.3389/fimmu.2018.02050.


FcγRIIIa Signaling Modulates Endosomal TLR Responses in Human CD4 T Cells.

Chauhan A J Immunol. 2017; 198(12):4596-4606.

PMID: 28500073 PMC: 5505339. DOI: 10.4049/jimmunol.1601954.


References
1.
Mastellos D, Germenis A, Lambris J . Complement: an inflammatory pathway fulfilling multiple roles at the interface of innate immunity and development. Curr Drug Targets Inflamm Allergy. 2005; 4(1):125-7. DOI: 10.2174/1568010053622993. View

2.
Esser A, KOLB W, Podack E, MULLER-EBERHARD H . Molecular reorganization of lipid bilayers by complement: a possible mechanism for membranolysis. Proc Natl Acad Sci U S A. 1979; 76(3):1410-4. PMC: 383261. DOI: 10.1073/pnas.76.3.1410. View

3.
Nimmerjahn F, Ravetch J . Fcgamma receptors as regulators of immune responses. Nat Rev Immunol. 2007; 8(1):34-47. DOI: 10.1038/nri2206. View

4.
Dashiell S, Rus H, Koski C . Terminal complement complexes concomitantly stimulate proliferation and rescue of Schwann cells from apoptosis. Glia. 2000; 30(2):187-98. DOI: 10.1002/(sici)1098-1136(200004)30:2<187::aid-glia8>3.0.co;2-7. View

5.
Bossi F, Fischetti F, Pellis V, Bulla R, Ferrero E, Mollnes T . Platelet-activating factor and kinin-dependent vascular leakage as a novel functional activity of the soluble terminal complement complex. J Immunol. 2004; 173(11):6921-7. DOI: 10.4049/jimmunol.173.11.6921. View